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Abstract
The industrial-scale manufacturing of viruses or virus-like particles in cell culture is nec-
essary for gene therapy and the treatment of cancer with oncolytic viruses. Complex 
multistep processes are required in both cases, but the low virus titers in batch cultures 
and the temperature sensitivity of the virus particles limit the production scale. To meet 
commercial and regulatory requirements, each process must be scalable and reproduc-
ible and must yield high virus titers. These requirements are met by establishing a cell 
culture process that matches the properties of the virus/host-cell system and by using 
serum-free cell culture medium. This chapter focuses on two case studies to consider 
the different aspects of process design, such as the reactor configuration and operational 
mode: the continuous production of retroviral pseudotype vectors in a retroviral pack-
aging cell line and the production of oncolytic measles virus vectors for cancer therapy.
Keywords: virus production, cultivation systems, online monitoring, measles, 
retrovirus
1. Introduction
Virus production techniques were originally developed for the manufacture of vaccines, but 
they are now becoming more important in other areas of the biopharmaceutical industry 
[1]. The scope for therapeutic strategies has broadened and now encompasses vectors for 
replacement protein expression, gene therapy and the treatment of cancer [2, 3]. Viruses for in 
vivo applications show a limited affinity for their target cells, they are generally unstable and 
large doses of infective virus particles (up to 1012 active virus particles per dose) are needed to 
achieve a therapeutic effect. Effective upstream production must therefore be combined with 
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optimized downstream processing. The production of viruses with clinical applications also 
raises important product safety requirements [4]. Bioprocess design for virus or virus vector 
production therefore depends strongly on the virus/host cell interactions and the kinetics of 
virus particle synthesis and virus release. There is no overall optimal process for virus pro-
duction, and each system must be optimized on a case-by-case basis.
In this chapter, we introduce two virus production processes as case studies, emphasizing 
the differences in process design. The first case involves the murine leukemia virus (MLV) 
carrying the human immunodeficiency virus (HIV-1) envelope protein, produced using the 
retroviral packaging cell line TELCeB6/pTr712-K52S (K52S). The second case involves the 
production of oncolytic measles virus and considers process design options for lytic viruses.
1.1. Vectors for gene therapy
Somatic gene therapy involves the transfer genes into an organism with the aim of replacing 
and repairing genes in somatic cells, thus curing the disease without affecting healthy cells 
rather than providing symptomatic relief [5, 6]. Efficient, non-toxic vectors have to be devel-
oped for delivering foreign genetic materials into specific cells. Ideally, viral vectors harness 
the viral infection pathway without the expression of viral genes, which leads to replication, 
triggerring the disease [7]. Stable vectors are required because of the long residence times in 
vivo. These treatments typically involve doses of 100–1000 mL with a virus density of at least 
106–107 infective units per mL.
Gene therapy is currently used in ongoing clinical trials for the treatment of cancer [8], heredi-
tary diseases [9], infectious diseases such as HIV infection [10, 11] and tissue engineering 
[12]. The replication of the virus particle must be inactivated to ensure that the vector itself 
does not cause a disease. Furthermore, all pathogenic virus genes must also be removed. The 
most effective way to do this is to generate virus-like particles (VLPs) that do not contain any 
viral genetic material. However, pseudotyping is an alternative approach in which the normal 
virus envelope proteins are replaced with those from another virus, either to improve stability 
or to favor interactions with particular host cells.
Non-replicating viral vectors for gene therapy are typically expressed in packaging cell lines 
containing only the essential structural virus genes [13]. This results in a virus construct that 
contains therapeutic RNA and regulatory elements to activate gene expression. The packag-
ing cell lines thus continuously release RNA-containing vector particles into the medium. 
Established packaging cell lines can produce retroviral particles over a long period depend-
ing on their growth characteristics and are suitable for pilot-scale processes with a bioreactor 
volume of up to 50 L [14, 15].
This chapter describes the cultivation of the retroviral packaging cell line TELCeB6/pTr712-
K52S (K52S). The cell line in this case study was derived from the env-negative MLV pack-
aging cell line TELCeB6 by transfecting the HIV-1 env gene using plasmid pTr712 [16–18]. 
This results in the production of MLV(HIV-1) vector particles containing the transfer vec-
tor MFGlnslacZ. MLV/HIV-pseudotyped retroviral vectors can transduce human primary T 
lymphocytes [19] and are therefore suitable for the treatment of cutaneous T-cell lymphomas 
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[20], making them an effective tool for gene therapy. An efficient production process is neces-
sary because one therapeutic dose typically requires 1010–1011 colony-forming units (cfu) per 
dose [17].
1.2. Oncolytic viruses
Over 60% of all ongoing clinical gene therapy trials worldwide deal with cancer. For this 
reason, cancer is by far the most common disease treated by viral vectors [21]. A promising 
approach is the inactivation of oncogenes or the activation of tumor suppressor genes. While 
oncogenes enhance cell proliferation, tumor suppressor genes induce apoptosis. The combi-
nation of chemotherapy and gene therapy will especially result in an effective suicide gene 
strategy [22]. Oncolytic viruses have a special status in the field of therapeutic viruses. Such 
viral particles kill tumor cells via two major mechanisms: (a) killing selective “degenerated” 
cells and (b) inducing a systemic anti-tumor immunity response [23]. Several research groups 
have attempted to increase the natural oncolytic effect of these viruses by genetic modification. 
For example, the immune response can be increased by modifying the expression of proteins 
such as granulocyte-macrophage colony–stimulating factor (GM-CSF) [24, 25] or by display-
ing the human carcinoembryonic antigen (CEA) [26–28]. Another strategy is the insertion of 
a tumor-specific promoter, which restricts viral expression to tumor cells [29]. Viral tropism 
can be engineered by displaying ligands that bind to cell surface receptors unique to cancer 
cells [10, 30–32]. Several genetically modified viruses have been adapted as potent oncolytic 
agents for clinical trials, including herpesvirus [33], adenovirus [34], poxvirus [35], coxsacki-
evirus [36], polyovirus [37], Newcastle disease virus [38] and reovirus [39]. In October 2015, 
the US Food and Drug Administration (FDA) granted approval for the first oncolytic virus 
(talimogene laherparepvec or T-VEC, brand name IMLYGIC) indicated for cutaneous and 
nodal melanoma. In January 2016, this product was also approved in the European Union.
Another oncolytic virus candidate is the measles virus. Attenuated measles virus vaccines 
have been used for several decades [40] with an excellent safety profile following the adminis-
tration of millions of doses. Measles virus particles have a high natural affinity for tumor cells 
because they favorably interact with certain tumor surface receptors such as nectin-4 [41]. The 
therapeutic concept takes advantage of both the specificity of the virus for tumor cells and of 
the lytic nature of a measles virus infection. Derivatives of measles virus vaccine strains are 
currently undergoing clinical testing for their efficacy in oncolytic virotherapy [42]. However, 
the broad application of measles virus in cancer therapy can only be successful if high titers 
of pure infectious virus particles can be manufactured. As discussed above for gene therapy 
vectors, oncolytic measles virus doses of 109–1012 particles are required per person and appli-
cation [42].
The production of oncolytic measles virus was initially based on the process used to produce 
measles vaccines, but the requirements are quite different. First, animal-derived medium com-
ponents are suitable for vaccine production but are not suitable for the manufacture of onco-
lytic vectors. Second, significantly higher titers of active, non-attenuated virus are required 
[43, 44]. This is by far the biggest issue in the field of oncolytic measles virus therapy because 
the therapeutic dose is 104–107 greater than the dose required for vaccination.
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2. Bioprocess design
2.1. Product inactivation
Bioprocess design for the manufacturing of viral particles is strongly determined by the 
characteristics of the virus product. One major problem is the inactivation kinetics and the 
resulting negative effect on virus yield. In general, enveloped viruses are less stable against 
physicochemical stress than non-enveloped viruses [45]. Viruses suitable for gene therapy, 
e.g. herpesvirus particles, are sensitive towards heat [46, 47], low pH and low osmolality [48, 
49]. The stability of some enveloped viruses against inactivation due to temperature or osmo-
lality effects can be increased by adding stabilizer to the culture medium such as sucrose, 
glycerol, trehalose or a compatible solute [50–52].
In both of the case studies, thermal inactivation is a crucial factor that leads to the substantial 
loss of virus particles during cultivation. Typically, animal cell lines show the highest growth 
rate at a process temperature of 37°C. However, at 37°C, measles virus and retroviruses 
have half-lives of approximately 1 h and 6–7 h, respectively [46, 53]. There are two realistic 
options to avoid thermal inactivation: (a) reducing the process temperature or (b) harvest-
ing the virus continuously, thereby achieving the rapid and efficient cooling of the product 
stream. However, a lower process temperature slows down host cell metabolism, which in 
turn reduces the virus titer. Therefore, the objective is to find an optimal temperature at which 
the virus production rate is higher than the inactivation rate. The former is dependent on the 
host cell and the latter on the virus. Retroviral vectors are known to be more stable if they 
are produced at 37°C. Vectors produced at 32°C are more rigid because of higher cholesterol 
content. This higher cholesterol content leads to a lower stability [54, 55]. In contrast, measles 
viruses showed a higher stability produced at 32°C [53]. The bioreactor system must eliminate 
as many factors as possible that reduce virus yields and should provide a suitable environ-
ment for the cells, avoiding additional stress caused by shear forces or nutrient limitation.
2.2. Bioreactor selection
The type of bioreactor system is primary defined by the growth characteristics of the host 
cells. Animal cells grow either in suspension or as adherent cells, and several bioreactor sys-
tems have been established to meet their requirements. Subject to this distinction, bioreactor 
systems can be divided into three classes: static systems, semi-dynamic systems and dynamic 
systems (Figure 1).
Static cultivation systems are the simplest to handle, but the lack of power input (aeration 
or agitation) limits their use to screening studies rather than production. Semi-dynamic sys-
tems retain the cells while supplying them with fresh medium. This power input and con-
vective mass transfer achieves a better nutrient supply at reasonable shear stress levels, but 
cell growth is heterogeneous and there is a lack of effective online/inline monitoring sys-
tems. Therefore, the most frequently used and well-characterized bioreactors are dynamic 
cultivation systems. These have a controlled power input, ensuring the homogeneous mix-
ing of suspension cells and anchorage-dependent adherent cells growing on microcarriers. 
However, dynamic  cultivation systems are a double-edged sword because the homogeneity 
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of cell growth comes at the expense of high shear stress [56, 57]. Adherent cell lines can be 
shielded from shear forces by using porous carriers, and macroporous carriers are advanta-
geous despite mass transfer limitations.
There is no optimal bioreactor for all virus production processes and the most suitable system 
must be chosen for each combination of virus and host cell, based on cell growth characteris-
tics and virus infection kinetics. We will consider the most important parameters for our two 
case studies, seeking a balance between the advantages and disadvantages of the different 
systems.
2.2.1. Bioreactor selection for continuous retrovirus production
The MLV(HIV-1)-pseudotyped vector is released continuously by the adherent retroviral 
packaging cell line as discussed above. The harvesting strategy has a significant influence on 
the virus particle yield, so the bioreactor system must achieve the rapid and continuous col-
lection of virus particles while ensuring total host cell retention. The best systems for this pur-
pose are fixed-bed or hollow fiber bioreactors [17, 58]. Both systems immobilize cells to ensure 
complete cell retention. However, a fixed-bed bioreactor containing macroporous carriers can 
support a larger number of cells than a hollow fiber bioreactor because of the greater growth 
surface area, a key determinant of the product yield (Figure 2). Continuous virus production 
in fixed-bed bioreactors can maintain high performance over a production time of longer than 
3 weeks. Virus purification and concentration were achieved using an integrated filtration 
system based on ceramic membranes [16–18]. Advantages of ceramic membranes are physi-
cal and chemical stability, durability (high expected lifetime), a narrow pore size distribution 
and a low potential for irreversible fouling. In addition, ceramic membranes are suitable for 
Figure 1. Overview of typical bioreactor systems for virus production.
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sterilization in place (by, e.g., steam) [59]. However, the major advantage compared to organic 
membranes is the lack of organic extractables and leachables. For the use of a separation sys-
tem in a continuous production process with a process time of several weeks, this fact is very 
important for the safety of the product [59, 60].
This process setup is superior to standard processes for the continuous production of degrad-
able bioactive products because the product can be transferred from the culture medium to 
more suitable conditions (e.g. low temperature) and less handling is required compared to 
cultivation in standard culture flasks.
2.2.2. Bioreactor selection for measles virus production
In contrast to pseudotype vector production using a continuously infected packaging cell line, 
measles virus infection causes the total lysis of the host cells. The production cycle is therefore 
much shorter and the supernatant contains a high content of host cell proteins and other cell 
debris. Measles virus particles are typically produced using adherent Vero, HeLa or MRC-5 
cells [43, 61, 62], so the cultivation system must provide a large growth surface area. The 
need to separate lysed cells from the supernatant overcomes the advantage of host cell reten-
tion in a fixed-bed bioreactor, so hollow fiber bioreactors or dynamic systems are preferable. 
However, this means that the other limitations of each bioreactor must be considered. Hollow 
fiber bioreactors require an external oxygenation system and a high circulation rate to achieve 
an adequate oxygen supply [63]. These demands on process design together with the large 
titers required for oncolytic therapy make the scale up of hollow fiber bioreactors unfeasible. 
To meet the necessary production scale and the power per dose, microcarrier-based dynamic 
cultivation systems are more effective than semi-dynamic systems. A stirred tank bioreactor is 
therefore preferable for the production of oncolytic measles virus particles (Figure 3).
One major drawback of stirred tank bioreactors is the shear force applied to the cells, 
which places limits on the maximum power input. Even so, the efficient suspension of the 
Figure 2. Continuous production process for MLV pseudotyped with the HIV-1 envelope protein in retroviral packaging 
cell line TELCeB6/pTr712-K52S (K52S).
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 microcarrier must be ensured to maintain homogeneous culture conditions. Proof of feasibil-
ity has been demonstrated by the cultivation of human mesenchymal stem cells at the 50 L 
scale without any deterioration in quality [64]. Because measles virus is characterized by a 
high rate of inactivation, the harvesting step must be carefully optimized. The continuous har-
vesting of lytic viruses produces large volumes of supernatant containing low concentrations 
of virus particles. Therefore, discontinuous harvesting strategies adapted to the lytic virus 
infection cycle can achieve better results. The best time for harvest has to be determined for 
each virus and host cell combination, and the optimal process mode depends on the kinetics 
of virus release.
2.3. Selection of the process mode
Process mode selection is one of the most challenging aspects of process design because all the 
advantages and drawbacks must be evaluated correctly. Virus production typically involves 
a two-step process: host cell expansion followed by the production phase (Figure 4). A deep 
understanding of the interaction between the host cell and virus is essential. Several critical 
parameters have been identified, including the host cell concentration at the time of infection 
(CCI) and the multiplicity of infection (MOI). These factors can be used to develop optimal 
strategies for process control.
2.3.1. Cell concentration at infection
The host cell is clearly a key factor in any virus production process, and for a wide range of 
processes, the mass of virus particles is linearly related to the number of host cells producing 
them. This is true for continuous production using packaging cell lines, but in other cases, 
increasing the cell density eventually causes the density-dependent inhibition of mitosis and 
Figure 3. Bioreactor system for the production of oncolytic measles virus particles in perfusion mode.
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therefore reduces the virus yields [65]. The survival and growth of each cell line, as well as 
the production of viruses, are also dependent on a specific and individual minimum cell con-
centration [66]. This interdependency becomes more complex when additional factors such 
as virus infection kinetics, cytopathic effects are considered. Generally, a high virus yield 
requires an optimal CCI, although the CCI has only a minor effect on the yield of measles virus 
[44]. This is because a continuous supply of fresh uninfected host cells is required for the pro-
duction of measles virus, to replenish the cells that are lost through lysis. Furthermore, several 
viruses (including measles virus) inhibit the cell cycle and thus affect cell growth [67, 68]. This 
can also influence the product yield, e.g., in the baculovirus-infected insect cell system the 
production of VLPs decreases when cells are infected during the late growth phase [69].
2.3.2. Multiplicity of infection
The MOI is the ratio of infective virus particles to host cell number and this can also influence 
the infection process. In the context of continuous production, the MOI is only of interest 
when generating a new packaging cell line [70]. In contrast, the MOI is a critical parame-
ter when optimizing the production of lytic viruses used for the synthesis of recombinant 
proteins. Theoretically, in the best-case scenario, the termination of protein synthesis would 
coincide with medium depletion just prior to cell lysis [71]. This is also necessary during the 
production of lytic therapeutic viruses in order to recover active virus particles. Two infection 
strategies can be used for process optimization depending on the particular virus/host cell 
system. If the objective is a synchronous infection, then a large number of infective virus par-
ticles should be used (MOI >> 1). A lower titer of infective viruses (MOI < 1) would result in 
a multiple-step virus amplification due to secondary infection of cells [72, 73]. Both strategies 
can amplify the virus yield by several hundred-fold when appropriately deployed. Aggarwal 
et al. [74] were able to increase the virus yield simply by using a lower MOI, but the character-
istics of the virus strain should always be kept in mind because the outcome strongly depends 
on the biological system [75]. For the production of measles virus, a higher MOI can reduce 
the yield of active virus particles [44]. However, the behavior of each host cell/virus combina-
tion must always be studied in the context of the cultivation system. The MOI was shown to 
have a significant impact on virus yields in a static cultivation experiment in T-flasks, whereas 
in a stirred tank bioreactor the titer stayed within the same order of magnitude even if the 
MOI varied substantially (0.0005, 0.001 and 0.02) [44].
Figure 4. Substrate cascade during a virus production process. Initially, a sufficient supply of nutrients to the host cells 
must be ensured, but then the host cells become the substrate for virus production.
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2.4. Process control
Reproducible, high-titer processes require appropriate measurement and control systems, 
including the established parameters of pH, temperature and oxygen concentration. However, 
real-time or online/inline monitoring and control systems for virus quantification are lacking, 
especially for the dynamic infection processes that characterize lytic virus production. Offline 
measurement methods are established and validated for several decades, but there are two 
major disadvantages. On the one hand, intervention in an operational system bears the risk 
of contaminations and on the other hand the lack of real-time data. Thus, it appears that 
online or inline measurement method should be preferred. The FDA has addressed this issue 
by launching the process analytical technology (PAT) initiative [76], whereas the European 
Medicines Agency (EMA) has implemented the similar concept of continuous process verifi-
cation [77]. To fulfil these demanding requirements, bioreactor systems have been fitted with 
diverse monitoring systems including near infrared spectroscopy, and in situ microscopy 
[78–80]. Multivariate data analysis is then applied to determine a benchmark known as the 
“golden batch”. Subsequent batches are evaluated against this standard, and if the signals 
do not fall within certain tolerances then the process is aborted. This strategy usually lacks 
process control opportunities and large numbers of failed batches are generated. The in-line 
measurement of important media components, and parameters for the online evaluation of 
process reproducibility and stability, thus remain among the unsolved problems of industrial 
biotechnology [81, 82].
One example of the above is the measurement of cell numbers in static or semi-dynamic 
cultivation systems. Offline, cell number could be determined, e.g., by membrane leakage 
assays (e.g. Trypan blue staining) or mitochondrial activity assays (e.g. WST-1 assay). In 
small scale, microscopy-based cell counting devices for static cultivation systems are also 
available [83]. Typically online, these data are collected by indirect inline measurement, e.g. 
by estimating the cell number based on the oxygen demand or glucose consumption rate 
of adherent cells growing in semi-dynamic cultivation systems [58, 84, 85]. In a fixed-bed 
bioreactor, this is realized by the simultaneous measurement of oxygen concentrations at 
the inlet and outlet. Oxygen demand is tightly coupled to cellular metabolism and strongly 
affected by virus infection, so the estimates are often inaccurate. Dielectric spectroscopy 
is a promising alternative approach for the inline quantification of host cells because the 
measurement is decoupled from metabolism and is based on the passive dielectric proper-
ties of cells in a conductive medium. When an alternating electric field is applied to the 
cell suspension culture, the cell membranes act as small capacitors leading to a buildup of 
electrical charge (polarization). The overall capacitance is thereby dependent on the fre-
quency of the alternating electric field (usually in the range 0.1–10 MHz), as well as the cell 
size, morphology and cell concentration [86]. For suspension cultures with a uniform cell 
size, this technique is appropriate for host cell quantification because there is a correlation 
between the recorded permittivity and cell number. Dielectric spectroscopy can also be 
used for the online quantitation of adherent cells, which usually requires cell detachment 
and offline cell counting. Dielectric spectroscopy can thus be used for the online monitor-
ing of cell attachment and growth as shown during measles virus production (Figure 5A 
and B).
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However, the permittivity signal is disrupted almost as soon as cells are infected. Dielectric 
spectroscopy readings are therefore strongly influenced by the cytopathic effect of the mea-
sles virus on the host cell (e.g. the formation of syncytia) and subsequent virus release. These 
changes in morphology also influence the permittivity signal (Figure 5C). Because the online 
quantification of virus particles is not possible, such morphological changes can be used for 
process control by calculating the Cole-Cole exponent parameter α. This is a dimensionless 
number with a value between 0 and 1 that nominally describes the distribution of relaxation 
times in the suspension, or the homogeneity of the cell population. In a homogenous cell sus-
pension culture, the initial release of virus particles can be detected because the α parameter 
declines 24 h post-infection (Figure 6).
The value of α is also influenced by changes in cell morphology. This can be shown by com-
paring homogenous cell suspension cultures and adherent cells growing on microcarriers 
when both are infected with measles virus (Figure 7). The signal corresponding to virus 
release is superimposed on signals representing changes in cell morphology (e.g. the forma-
tion of syncytia), which makes data interpretation and process control more challenging. For 
the production of the lytic measles virus, dielectric spectroscopy can be used to ensure that 
cells are infected at the same point in the growth phase and to determine when virus particles 
are released, making it an ideal tool for process control in dynamic cultivation systems.
Figure 5. Impedance spectrometer readings during the production of measles virus using Vero cells growing on Cytodex 
1 microcarriers in a 1-L stirred tank bioreactor. A: Cell adhesion to the microcarrier at a very high initial cell concentration 
of 80,000 cells per cm2. B: Cell growth in the bioreactor. C: Addition of 0.5-L fresh culture medium with simultaneous 
virus infection.
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Figure 6. Virus release from a Burkitt’s lymphoma cell line infected with measles virus.
Figure 7. Distribution of relaxation times in the suspension (Cole-Cole exponent parameter α) of adherent cells (■) and 
cell suspension cultures (○).
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3. Conclusion
Different production processes were established in each of our case studies by taking into 
account the requirements of the host cells and products, and the benefits and limitations of 
each type of bioreactor. The system of choice for the continuous production of pseudotype 
vector MLV(HIV-1) using the retroviral packaging cell line TELCeB6/pTr712-K52S (K52S) was 
the fixed-bed bioreactor (Figure 2). The cells were cultivated in a vessel packed with FibraCell 
macroporous carriers, with a working volume of 200 mL and an inner diameter of 56 mm. 
Perfusion of the immobilized cells was achieved using an additional vessel (working volume 
2 L) for medium conditioning, and process parameters such as dissolved oxygen and pH were 
monitored and controlled in this vessel. Cell growth in the fixed-bed bioreactor could not be 
monitored using dielectric spectroscopy because of the small measuring volume, reflecting 
the fixed positions of the probe and the carrier. Cell concentration was therefore estimated 
based on the oxygen consumption rate, determined by the simultaneous measurement of 
oxygen concentrations at the inlet and outlet.
The perfused medium was preheated to 37°C, and the viral vectors were harvested contin-
uously to improve vector stability and host cell productivity using an integrated filtration 
system [17]. To ensure optimal substrate consumption and yield, a portion of the virus-free 
filtrate was recycled to the conditioning vessel of the fixed-bed bioreactor [16, 18]. The tubu-
lar filtration unit comprised an Al
2
O
3
 support coated with asymmetric layers of ZrO
2
 and 
TiO
2
. The tubular membrane had an outer diameter of 25 mm and 19 inner tubes each with a 
diameter of 3 mm, with a molecular weight cut-off of 20 kDa (Innovations GmbH, Gladbeck, 
Germany). Filtration was performed at a flow rate of 2 L min−1 and a transmembrane pressure 
of 0.4 bar. This combination of membrane type and operational mode allowed continuous 
filtration for more than 400 h. Virus production was tested in batch mode to confirm the effi-
ciency of the reactor setup. The maximum virus titer of 2.76 × 109 cfu was achieved in perfu-
sion mode, whereas the maximum yield in batch mode was only 1.4 × 106 cfu [16–18]. This 
probably reflects the higher volumetric throughput of perfusion mode and the low stability 
of the virus particles at the production temperature.
The design of a continuous production process for measles virus is more challenging because 
virus release depends on the lysis of the adherent, growing host cells. In contrast to packaging 
cell lines, the host cells are consumed during the production of lytic viruses, which limits the 
length of the production cycle and also the yields. A microcarrier based cultivation system 
was established to ensure the continuous supply of fresh host cells in a scalable system. Cells 
growing on Cytodex 1 microcarriers in a stirred tank bioreactor were detached by incubation 
for 10 min in PBS containing 0.025% TrypZean and 0.01% EDTA, thus enabling bead-to-bead 
transfer. This provided a seed train from T-flasks to a large-scale stirred tank bioreactor and 
the addition of up to 75% fresh microcarrier [87, 88]. As discussed above for the pseudotyped 
vector, the process temperature was the most critical process parameter for the production 
of measles virus. Process temperature optimization in different cultivation systems led to 
contradictory results [44]: in a static cultivation system (T-flasks) and in a stirred tank bio-
reactor, the highest virus titers were achieved at a cultivation temperature of 32°C, but in 
small-scale dynamic cultivation systems (spinner flasks) the highest titers were achieved at 
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37°C. However, both cultivation temperatures resulted in severe thermal virus inactivation 
and continuous harvesting was therefore necessary. Filtration during cultivation is challeng-
ing due to the rapid accumulation of host cell proteins (including proteases) and cell debris in 
the surrounding medium caused by cell lysis, resulting in the blocking of membrane pores. 
Furthermore, measles virus particles range in size from 300 nm to 1 μm [89]. The blocking of 
filter pores by debris and the particle size range of the virus make discontinuous filtration 
more appropriate. Regardless of the cultivation system, the best process mode was repeated 
batch mode with a daily virus harvest [44]. Using this setup (Figure 3), virus titers of up to 
7.4 × 109 median tissue culture infective dose (TCID50) can be managed in a working volume of 500 mL containing 3 g L−1 Cytodex 1.
The analysis of these two representative processes provides insight into the challenges of pro-
cess design when using sensitive viral production systems. As stated above, there is no perfect 
process, but the best process for each combination of host cell and product can be determined 
by considering as many parameters as possible in order to maximize the product yield. Many 
investigations are still required to satisfy the demands of large-scale virus production, for 
both the pseudotype vector and the oncolytic measles virus. The virus/host cell system must 
be understood in detail to facilitate the development of an appropriate production process 
which reproducibly produces sufficient yields of high-quality virus particles.
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